Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

3rd Immunotherapy of Cancer Conference (ITOC3) /
Is PD-L1 really a predictive biomarker?

21st - 23rd Mar 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.04.16
Views: 2236

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

Dr Ascierto talks to ecancertv at ITOC-3 about PD-L1 checkpoint inhibition. In particular, he discusses whether or not it can be truly considered as a predictive biomarker.

PD-L1 has been a target of research due to its role in regulation of host immune response to cancerous cells. PD-L1 positive tumour cells have been shown to be especially susceptible to immunotherapy.

However, Dr Ascierto reports that stratification of patients based on PD-L1 expression does not match with patient response to treatment.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation